|
1
|
Klingenberg R and Hansson GK: Treating
inflammation in atherosclerotic cardiovascular disease: emerging
therapies. Eur Heart J. 30:2838–2844. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moore KJ and Tabas I: Macrophages in the
pathogenesis of atherosclerosis. Cell. 145:341–355. 2011.
View Article : Google Scholar
|
|
3
|
Hansson GK and Hermansson A: The immune
system in atherosclerosis. Nat Immunol. 12:204–212. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reiss AB and Cronstein BN: Regulation of
foam cells by adenosine. Arterioscler Thromb Vasc Biol. 32:879–886.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McLaren JE, Michael DR, Ashlin TG and
Ramji DP: Cytokines, macrophage lipid metabolism and foam cells:
implications for cardiovascular disease therapy. Prog Lipid Res.
50:331–347. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Glass CK and Saijo K: Nuclear receptor
transrepression pathways that regulate inflammation in macrophages
and T cells. Nat Rev Immunol. 10:365–376. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Villacorta L, Schopfer FJ, Zhang J, et al:
PPARgamma and its ligands: therapeutic implications in
cardiovascular disease. Clin Sci (Lond). 116:205–218. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bouhlel MA, Staels B and Chinetti-Gbaguidi
G: Peroxisome proliferator-activated receptors - from active
regulators of macrophage biology to pharmacological targets in the
treatment of cardiovascular disease. J Intern Med. 263:28–42.
2008.
|
|
9
|
Rigamonti E, Chinetti-Gbaguidi G and
Staels B: Regulation of macrophage functions by PPAR-alpha,
PPAR-gamma, and LXRs in mice and men. Arterioscler Thromb Vasc
Biol. 28:1050–1059. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tabas I: Macrophage death and defective
inflammation resolution in atherosclerosis. Nat Rev Immunol.
10:36–46. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Martinez FO, Helming L and Gordon S:
Alternative activation of macrophages: an immunologic functional
perspective. Annu Rev Immunol. 27:451–483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takano H and Komuro I: Peroxisome
proliferator-activated receptor gamma and cardiovascular diseases.
Circ J. 73:214–220. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lamers C, Schubert-Zsilavecz M and Merk D:
Therapeutic modulators of peroxisome proliferator-activated
receptors (PPAR): a patent review (2008-present). Expert Opin Ther
Pat. 22:803–841. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kajinami K and Kawai Y: Beyond C-reactive
protein; new evidence for another inflammatory biomarker predicting
cardiovascular disease risk. Atherosclerosis. 214:39–40. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lawrence CB, Brough D and Knight EM: Obese
mice exhibit an altered behavioural and inflammatory response to
lipopolysaccharide. Dis Model Mech. 5:649–659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lloyd-Jones D, Adams RJ, Brown TM, et al:
American Heart Association Statistics Committee and Stroke
Statistics Subcommittee: Executive summary: heart disease and
stroke statistics - 2010 update: a report from the American Heart
Association. Circulation. 121:948–954. 2010. View Article : Google Scholar
|
|
17
|
Zhao Y, Pennings M, Vrins CL, et al:
Hypocholesterolemia, foam cell accumulation, but no atherosclerosis
in mice lacking ABC-transporter A1 and scavenger receptor BI.
Atherosclerosis. 218:314–322. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Uto-Kondo H, Ayaori M, Ogura M, et al:
Coffee consumption enhances high-density lipoprotein-mediated
cholesterol efflux in macrophages. Circ Res. 106:779–787. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ogawa Y, Yoneda M, Tomeno W, et al:
Peroxisome proliferator-activated receptor gamma exacerbates
Concanavalin A-induced liver injury via suppressing the
translocation of NF-κB into the nucleus. PPAR Res.
2012:9403842012.PubMed/NCBI
|
|
20
|
Norazmi MN, Mohamed R, Nurul AA and Jaacob
NS: The modulation of PPARγ1 and PPARγ2 mRNA expression by
ciglitazone in CD3/CD28-activated naïve and memory CD4+
T cells. Clin Dev Immunol. 2012:8491952012.
|
|
21
|
Tobiasova Z, Zhang L, Yi T, et al:
Peroxisome proliferator-activated receptor-γ agonists prevent in
vivo remodeling of human artery induced by alloreactive T
cells. Circulation. 124:196–205. 2011.
|
|
22
|
Visser ME, Witztum JL, Stroes ES and
Kastelein JJ: Antisense oligonucleotides for the treatment of
dyslipidaemia. Eur Heart J. 33:1451–1458. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Robinson SM and Mann DA: Role of nuclear
factor kappaB in liver health and disease. Clin Sci (Lond).
118:691–705. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tornatore L, Thotakura AK, Bennett J, et
al: The nuclear factor kappa B signaling pathway: integrating
metabolism with inflammation. Trends Cell Biol. 22:557–566. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kwak JH, Jung JK and Lee H: Nuclear
factor-kappa B inhibitors; a patent review (2006–2010). Expert Opin
Ther Pat. 21:1897–1910. 2011.
|
|
26
|
Kim IT, Ryu S, Shin JS, et al: Euscaphic
acid isolated from roots of Rosa rugosa inhibits LPS-induced
inflammatory responses via TLR4-mediated NF-κB inactivation in RAW
264.7 macrophages. J Cell Biochem. 113:1936–1946. 2012.PubMed/NCBI
|
|
27
|
Bright JJ, Kanakasabai S, Chearwae W and
Chakraborty S: PPAR regulation of inflammatory signaling in CNS
diseases. PPAR Res. 2008:6585202008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hirsch J, Johnson CL, Nelius T, et al:
PEDF inhibits IL8 production in prostate cancer cells through PEDF
receptor/phospholipase A2 and regulation of NFκB and PPARγ.
Cytokine. 55:202–210. 2011.PubMed/NCBI
|
|
29
|
Simone RE, Russo M, Catalano A, et al:
Lycopene inhibits NF-κB-mediated IL-8 expression and changes redox
and PPARγ signalling in cigarette smoke-stimulated macrophages.
PLoS One. 6:e196522011.
|
|
30
|
Fan B, Ikuyama S, Gu JQ, et al: Oleic
acid-induced ADRP expression requires both AP-1 and PPAR response
elements, and is reduced by Pycnogenol through mRNA degradation in
NMuLi liver cells. Am J Physiol Endocrinol Metab. 297:E112–123.
2009. View Article : Google Scholar : PubMed/NCBI
|
